MX2014004086A - Compuestos de pirrolopirimidina para el tratamiento del cancer. - Google Patents
Compuestos de pirrolopirimidina para el tratamiento del cancer.Info
- Publication number
- MX2014004086A MX2014004086A MX2014004086A MX2014004086A MX2014004086A MX 2014004086 A MX2014004086 A MX 2014004086A MX 2014004086 A MX2014004086 A MX 2014004086A MX 2014004086 A MX2014004086 A MX 2014004086A MX 2014004086 A MX2014004086 A MX 2014004086A
- Authority
- MX
- Mexico
- Prior art keywords
- compound
- alkyl
- further characterized
- cancer
- mmol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161542392P | 2011-10-03 | 2011-10-03 | |
| US201161547183P | 2011-10-14 | 2011-10-14 | |
| PCT/US2012/058298 WO2013052417A1 (en) | 2011-10-03 | 2012-10-01 | Pyrrolopyrimidine compounds for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2014004086A true MX2014004086A (es) | 2014-09-22 |
Family
ID=48044101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014004086A MX2014004086A (es) | 2011-10-03 | 2012-10-01 | Compuestos de pirrolopirimidina para el tratamiento del cancer. |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US9273056B2 (OSRAM) |
| EP (1) | EP2763988B1 (OSRAM) |
| JP (2) | JP2014532060A (OSRAM) |
| KR (1) | KR102063098B1 (OSRAM) |
| CN (1) | CN103958510B (OSRAM) |
| AU (1) | AU2012318896B2 (OSRAM) |
| BR (1) | BR112014007788A2 (OSRAM) |
| CA (1) | CA2850617A1 (OSRAM) |
| ES (1) | ES2650630T3 (OSRAM) |
| IL (1) | IL231835A0 (OSRAM) |
| MX (1) | MX2014004086A (OSRAM) |
| RU (1) | RU2631655C2 (OSRAM) |
| WO (1) | WO2013052417A1 (OSRAM) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011146313A1 (en) | 2010-05-19 | 2011-11-24 | The University Of North Carolina At Chapel Hill | Pyrazolopyrimidine compounds for the treatment of cancer |
| BR112014007788A2 (pt) | 2011-10-03 | 2017-04-18 | Univ North Carolina Chapel Hill | compostos de pirrolopirimidina para tratamento do câncer |
| MX2014013632A (es) | 2012-05-22 | 2015-02-05 | Univ North Carolina | Compuestos de pirimidina para el tratamiento de cancer. |
| WO2014018535A1 (en) | 2012-07-25 | 2014-01-30 | Salk Institute For Biological Studies | Regulating the interaction between tam ligands and lipid membranes with exposed phosphatidylserine |
| US9562047B2 (en) | 2012-10-17 | 2017-02-07 | The University Of North Carolina At Chapel Hill | Pyrazolopyrimidine compounds for the treatment of cancer |
| WO2014085225A1 (en) | 2012-11-27 | 2014-06-05 | The University Of North Carolina At Chapel Hill | Pyrimidine compounds for the treatment of cancer |
| US9603850B2 (en) | 2014-04-11 | 2017-03-28 | The University Of North Carolina At Chapel Hill | MerTK-specific pyrazolopyrimidine compounds |
| CN106188060A (zh) * | 2015-04-29 | 2016-12-07 | 厦门大学 | 嘧啶并吡咯类化合物、其制备方法、药用组合物及其应用 |
| US9840503B2 (en) | 2015-05-11 | 2017-12-12 | Incyte Corporation | Heterocyclic compounds and uses thereof |
| WO2017027717A1 (en) | 2015-08-12 | 2017-02-16 | Incyte Corporation | Bicyclic fused pyrimidine compounds as tam inhibitors |
| US10053465B2 (en) | 2015-08-26 | 2018-08-21 | Incyte Corporation | Pyrrolopyrimidine derivatives as TAM inhibitors |
| US20180296561A1 (en) * | 2015-10-07 | 2018-10-18 | The University Of North Carolina At Chapel Hill | The Methods For Treatment Of Tumors |
| US10709708B2 (en) | 2016-03-17 | 2020-07-14 | The University Of North Carolina At Chapel Hill | Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor |
| WO2017172596A1 (en) | 2016-03-28 | 2017-10-05 | Incyte Corporation | Pyrrolotriazine compounds as tam inhibitors |
| AU2017326006B2 (en) * | 2016-09-16 | 2021-10-28 | Vitae Pharmaceuticals, LLC. | Inhibitors of the menin-MLL interaction |
| CN110177553A (zh) * | 2016-11-17 | 2019-08-27 | 北卡罗来纳大学教堂山分校 | 烷基吡咯并嘧啶类似物及其制备和使用方法 |
| CA3077308A1 (en) | 2017-09-27 | 2019-04-04 | Incyte Corporation | Salts of pyrrolotriazine derivatives useful as tam inhibitors |
| WO2019113190A1 (en) | 2017-12-07 | 2019-06-13 | Array Biopharma Inc. | Bicyclic fused pyridine compounds as inhibitors of tam kinases |
| CA3086714A1 (en) * | 2017-12-28 | 2019-07-04 | Development Center For Biotechnology | Heterocycle compounds as tyro3, axl and mertk (tam) family of receptor tyrosine kinase inhibitors |
| PL3813800T3 (pl) | 2018-06-29 | 2025-08-18 | Incyte Corporation | Formulacje inhibitora axl/mer |
| KR102163494B1 (ko) * | 2018-10-26 | 2020-10-08 | 한국과학기술연구원 | 단백질 키나아제 저해제인 헤테로방향족 매크로시클릭 유도체 |
| KR102848297B1 (ko) * | 2019-04-02 | 2025-08-20 | 메릭스 인코포레이티드 | 키나아제 억제제의 다형체, 이러한 화합물을 함유하는 약학 조성물, 제조 방법 및 용도 |
| AU2021230385A1 (en) | 2020-03-06 | 2022-09-22 | Incyte Corporation | Combination therapy comprising AXL/MER and PD-1/PD-L1 inhibitors |
| CN112043710A (zh) * | 2020-09-28 | 2020-12-08 | 广州智睿医药科技有限公司 | 一种治疗或预防与lrrk2激酶或异常lrrk2突变激酶活性相关疾病的药物 |
| CN115073469B (zh) * | 2021-03-15 | 2023-12-22 | 药雅科技(上海)有限公司 | 吡咯并嘧啶类化合物作为激酶抑制剂的制备及其应用 |
| WO2025170773A1 (en) * | 2024-01-26 | 2025-08-14 | The University Of North Carolina At Chapel Hill | Tam-family degraders and uses thereof |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5958930A (en) | 1991-04-08 | 1999-09-28 | Duquesne University Of The Holy Ghost | Pyrrolo pyrimidine and furo pyrimidine derivatives |
| WO1997049706A1 (en) * | 1996-06-25 | 1997-12-31 | Novartis Ag | SUBSTITUTED 7-AMINO-PYRROLO[3,2-d]PYRIMIDINES AND THE USE THEREOF |
| US20080248046A1 (en) | 1997-03-17 | 2008-10-09 | Human Genome Sciences, Inc. | Death domain containing receptor 5 |
| AR035885A1 (es) * | 2001-05-14 | 2004-07-21 | Novartis Ag | Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica |
| DE60228103D1 (de) | 2001-10-02 | 2008-09-18 | Smithkline Beecham Corp | Chemische verbindungen |
| DE10239042A1 (de) | 2002-08-21 | 2004-03-04 | Schering Ag | Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel |
| US7589086B2 (en) | 2003-05-28 | 2009-09-15 | Universita Degli Studi Di Siena | Substituted pyrazolo[3,4-D]pyrimidines as anti-tumor agents |
| US7504396B2 (en) | 2003-06-24 | 2009-03-17 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| GB0320728D0 (en) | 2003-09-04 | 2003-10-08 | Kilminster Shaun | Test |
| EA010160B1 (ru) | 2003-09-18 | 2008-06-30 | Конформа Терапьютикс Корпорейшн | Новые гетероциклические соединения - ингибиторы hsp90 и способы их получения |
| DE602005023587D1 (de) | 2004-01-21 | 2010-10-28 | Univ Emory | Zusammensetzungen und verwendung von tyrosinkinase-hemmern zur behandlung von pathogenen infektionen |
| CA2553724A1 (en) | 2004-02-03 | 2005-08-18 | Abbott Laboratories | Aminobenzoxazoles as therapeutic agents |
| PL1713806T3 (pl) * | 2004-02-14 | 2013-09-30 | Irm Llc | Związki i kompozycje jako inhibitory kinaz białkowych |
| US7956060B2 (en) | 2004-03-30 | 2011-06-07 | Kyowa Hakko Kirin Co., Ltd. | Pyrimidine derivative compound |
| JP4790703B2 (ja) * | 2004-04-07 | 2011-10-12 | 武田薬品工業株式会社 | 環式化合物 |
| GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| WO2006035067A2 (en) | 2004-09-30 | 2006-04-06 | Tibotec Pharmaceuticals Ltd. | Hiv inhibiting 5-heterocyclyl pyrimidines |
| WO2006042102A2 (en) * | 2004-10-05 | 2006-04-20 | Neurogen Corporation | Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds |
| EP1710246A1 (en) | 2005-04-08 | 2006-10-11 | Schering Aktiengesellschaft | Sulfoximine-pyrimidine Macrocycles and the salts thereof, a process for making them, and their pharmaceutical use against cancer |
| WO2007035963A2 (en) * | 2005-09-23 | 2007-03-29 | Conforma Therapeutics Corporation | Anti-tumor methods using multi drug resistance independent synthetic hsp90 inhibitors |
| US7547782B2 (en) | 2005-09-30 | 2009-06-16 | Bristol-Myers Squibb Company | Met kinase inhibitors |
| US7642266B2 (en) | 2005-10-06 | 2010-01-05 | Schering Corporation | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors |
| EA017812B1 (ru) | 2005-12-08 | 2013-03-29 | Медарекс, Инк. | Выделенное моноклональное антитело или его антигенсвязывающий участок, которые связываются с протеинтирозинкиназой 7 ( ptk7) человека, и их применение |
| WO2007075554A2 (en) | 2005-12-19 | 2007-07-05 | Osi Pharmaceuticals, Inc. | Combination of igfr inhibitor and anti-cancer agent |
| EP1803723A1 (de) | 2006-01-03 | 2007-07-04 | Bayer Schering Pharma Aktiengesellschaft | (2,4,9-triaza-1(2,4)-pyrimidina-3(1,3)-benzenacyclononaphan-3^4-yl)-sulfoximid derivate als selektive inhibitoren der aurora kinase zur behandlung von krebs |
| WO2007113254A1 (en) | 2006-03-30 | 2007-10-11 | Tibotec Pharmaceuticals Ltd. | Hiv inhibiting 5-amido substituted pyrimidines |
| US7998978B2 (en) | 2006-05-01 | 2011-08-16 | Pfizer Inc. | Substituted 2-amino-fused heterocyclic compounds |
| GB0610242D0 (en) | 2006-05-23 | 2006-07-05 | Novartis Ag | Organic compounds |
| JO3235B1 (ar) | 2006-05-26 | 2018-03-08 | Astex Therapeutics Ltd | مركبات بيررولوبيريميدين و استعمالاتها |
| AU2008296479A1 (en) | 2007-08-28 | 2009-03-12 | Dana Farber Cancer Institute | Amino substituted pyrimidine, pyrollopyridine and pyrazolopyrimidine derivatives useful as kinase inhibitors and in treating proliferative disorders and diseases associated with angiogenesis |
| NZ584454A (en) | 2007-10-12 | 2011-09-30 | Ingenium Pharmaceuticals Gmbh | N-[6-phenyl-pyrimidin-4-yl]-amides and urea derivatives as inhibitors of protein kinases |
| WO2010008411A1 (en) * | 2007-11-09 | 2010-01-21 | The Salk Institute For Biological Studies | Use of tam receptor inhibitors as immunoenhancers and tam activators as immunosuppressors |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| US8399206B2 (en) | 2008-07-10 | 2013-03-19 | Nodality, Inc. | Methods for diagnosis, prognosis and methods of treatment |
| US20120230991A1 (en) | 2008-07-29 | 2012-09-13 | Douglas Kim Graham | Methods and compounds for enhancing anti-cancer therapy |
| WO2010030781A2 (en) | 2008-09-10 | 2010-03-18 | Numed International, Inc. | Aromatic carboxylic acid derivatives for treatment and prophylaxis of gastrointestinal diseases including colon cancer |
| TW201016676A (en) | 2008-10-03 | 2010-05-01 | Astrazeneca Ab | Heterocyclic derivatives and methods of use thereof |
| GB0819105D0 (en) * | 2008-10-17 | 2008-11-26 | Chroma Therapeutics Ltd | Pyrrolo-pyrimidine compounds |
| WO2010068863A2 (en) | 2008-12-12 | 2010-06-17 | Cystic Fibrosis Foundation Therapeutics, Inc. | Pyrimidine compounds and methods of making and using same |
| WO2010085597A1 (en) | 2009-01-23 | 2010-07-29 | Incyte Corporation | Macrocyclic compounds and their use as kinase inhibitors |
| TW201102391A (en) * | 2009-03-31 | 2011-01-16 | Biogen Idec Inc | Certain substituted pyrimidines, pharmaceutical compositions thereof, and methods for their use |
| UA107791C2 (en) | 2009-05-05 | 2015-02-25 | Dow Agrosciences Llc | Pesticidal compositions |
| AR076550A1 (es) | 2009-05-06 | 2011-06-22 | Portola Pharm Inc | Inhibidores de la janus tirosina kinasa (jak) |
| JP5883384B2 (ja) | 2009-08-13 | 2016-03-15 | ザ ジョンズ ホプキンス ユニバーシティー | 免疫機能を調節する方法 |
| EA201200471A1 (ru) | 2009-09-10 | 2012-10-30 | Новартис Аг | Простые эфирные производные бициклических гетероарилов |
| WO2011065800A2 (ko) | 2009-11-30 | 2011-06-03 | 주식회사 오스코텍 | 피리미딘 유도체, 이의 제조방법 및 이를 함유하는 약학적 조성물 |
| WO2011103441A1 (en) | 2010-02-18 | 2011-08-25 | Schering Corporation | Substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
| GB201004311D0 (en) | 2010-03-15 | 2010-04-28 | Proximagen Ltd | New enzyme inhibitor compounds |
| WO2011133920A1 (en) | 2010-04-23 | 2011-10-27 | Cytokinetics, Inc. | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
| WO2011146313A1 (en) * | 2010-05-19 | 2011-11-24 | The University Of North Carolina At Chapel Hill | Pyrazolopyrimidine compounds for the treatment of cancer |
| WO2011153553A2 (en) | 2010-06-04 | 2011-12-08 | The Regents Of The University Of California | Methods and compositions for kinase inhibition |
| JP2014005206A (ja) | 2010-10-22 | 2014-01-16 | Astellas Pharma Inc | アリールアミノヘテロ環カルボキサミド化合物 |
| AU2011330730B2 (en) | 2010-11-18 | 2016-02-18 | Kasina Laila Innova Pharmaceuticals Private Limited | Substituted 4-(selenophen-2(or 3)-ylamino)pyrimidine compounds and methods of use thereof |
| US8362023B2 (en) | 2011-01-19 | 2013-01-29 | Hoffmann-La Roche Inc. | Pyrazolo pyrimidines |
| US9376438B2 (en) | 2011-05-17 | 2016-06-28 | Principia Biopharma, Inc. | Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors |
| CA2846431A1 (en) | 2011-08-29 | 2013-03-07 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
| CN103814030A (zh) * | 2011-09-22 | 2014-05-21 | 辉瑞大药厂 | 吡咯并嘧啶及嘌呤衍生物 |
| BR112014007788A2 (pt) | 2011-10-03 | 2017-04-18 | Univ North Carolina Chapel Hill | compostos de pirrolopirimidina para tratamento do câncer |
| WO2013124324A1 (en) | 2012-02-21 | 2013-08-29 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Tam receptors as virus entry cofactors |
| CA2869954C (en) | 2012-04-20 | 2023-01-03 | Advinus Therapeutics Limited | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof in medical conditions related to modulation of bruton's tyrosine kinase activity |
| MX2014013632A (es) | 2012-05-22 | 2015-02-05 | Univ North Carolina | Compuestos de pirimidina para el tratamiento de cancer. |
| US9562047B2 (en) | 2012-10-17 | 2017-02-07 | The University Of North Carolina At Chapel Hill | Pyrazolopyrimidine compounds for the treatment of cancer |
| WO2014085225A1 (en) | 2012-11-27 | 2014-06-05 | The University Of North Carolina At Chapel Hill | Pyrimidine compounds for the treatment of cancer |
| US20170202847A1 (en) | 2014-04-04 | 2017-07-20 | The University Of North Carolina At Chapel Hill | Methods for the treatment of tumors |
| US9603850B2 (en) | 2014-04-11 | 2017-03-28 | The University Of North Carolina At Chapel Hill | MerTK-specific pyrazolopyrimidine compounds |
-
2012
- 2012-10-01 BR BR112014007788A patent/BR112014007788A2/pt not_active IP Right Cessation
- 2012-10-01 AU AU2012318896A patent/AU2012318896B2/en active Active
- 2012-10-01 US US14/348,805 patent/US9273056B2/en active Active
- 2012-10-01 JP JP2014534626A patent/JP2014532060A/ja active Pending
- 2012-10-01 EP EP12839069.7A patent/EP2763988B1/en active Active
- 2012-10-01 WO PCT/US2012/058298 patent/WO2013052417A1/en not_active Ceased
- 2012-10-01 KR KR1020147010156A patent/KR102063098B1/ko active Active
- 2012-10-01 CA CA2850617A patent/CA2850617A1/en not_active Abandoned
- 2012-10-01 RU RU2014115847A patent/RU2631655C2/ru active
- 2012-10-01 MX MX2014004086A patent/MX2014004086A/es unknown
- 2012-10-01 CN CN201280056825.4A patent/CN103958510B/zh active Active
- 2012-10-01 ES ES12839069.7T patent/ES2650630T3/es active Active
-
2014
- 2014-03-31 IL IL231835A patent/IL231835A0/en unknown
-
2016
- 2016-02-03 US US15/014,573 patent/US9795606B2/en active Active
- 2016-12-28 JP JP2016255095A patent/JP6316925B2/ja active Active
-
2017
- 2017-10-23 US US15/790,700 patent/US10179133B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US10179133B2 (en) | 2019-01-15 |
| JP2014532060A (ja) | 2014-12-04 |
| IL231835A0 (en) | 2014-05-28 |
| US20160151372A1 (en) | 2016-06-02 |
| KR102063098B1 (ko) | 2020-01-08 |
| RU2014115847A (ru) | 2015-11-10 |
| US20180104247A1 (en) | 2018-04-19 |
| CA2850617A1 (en) | 2013-04-11 |
| WO2013052417A1 (en) | 2013-04-11 |
| CN103958510B (zh) | 2016-10-19 |
| JP6316925B2 (ja) | 2018-04-25 |
| AU2012318896B2 (en) | 2017-03-02 |
| US9273056B2 (en) | 2016-03-01 |
| EP2763988A1 (en) | 2014-08-13 |
| JP2017101043A (ja) | 2017-06-08 |
| EP2763988A4 (en) | 2015-06-03 |
| EP2763988B1 (en) | 2017-09-20 |
| CN103958510A (zh) | 2014-07-30 |
| KR20140095471A (ko) | 2014-08-01 |
| BR112014007788A2 (pt) | 2017-04-18 |
| ES2650630T3 (es) | 2018-01-19 |
| AU2012318896A1 (en) | 2014-05-22 |
| US9795606B2 (en) | 2017-10-24 |
| HK1201256A1 (en) | 2015-08-28 |
| RU2631655C2 (ru) | 2017-09-26 |
| US20140243315A1 (en) | 2014-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2012318896B2 (en) | Pyrrolopyrimidine compounds for the treatment of cancer | |
| US9744172B2 (en) | Pyrazolopyrimidine compounds for the treatment of cancer | |
| AU2013266438B2 (en) | Pyrimidine compounds for the treatment of cancer | |
| US9771330B2 (en) | Pyrimidine compounds for the treatment of cancer | |
| US9562047B2 (en) | Pyrazolopyrimidine compounds for the treatment of cancer | |
| CA2971024A1 (en) | Fused ring heteroaryl compounds and their use as trk inhibitors | |
| US20080319044A1 (en) | Compounds and Methods of Use Thereof | |
| WO2006050054A2 (en) | Compounds and methods of use thereof | |
| HK1201256B (en) | Pyrrolopyrimidine compounds for the treatment of cancer | |
| JP2025501049A (ja) | 三環式化合物、それを調製するための方法、及びその使用 | |
| WO2006063010A2 (en) | Compounds and methods of use thereof |